1
|
Huang S, Hu J, Hu M, Hou Y, Zhang B, Liu J, Liu X, Chen Z, Wang L. Cooperation between SIX1 and DHX9 transcriptionally regulates integrin-focal adhesion signaling mediated metastasis and sunitinib resistance in KIRC. Oncogene 2024; 43:2951-2969. [PMID: 39174859 DOI: 10.1038/s41388-024-03126-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2024] [Revised: 08/02/2024] [Accepted: 08/06/2024] [Indexed: 08/24/2024]
Abstract
High invasive capacity and acquired tyrosine kinase inhibitors (TKI) resistance of kidney renal clear cell carcinoma (KIRC) cells remain obstacles to prolonging the survival time of patients with advanced KIRC. In the present study, we reported that sine oculis homeobox 1 (SIX1) was upregulated in sunitinib-resistant KIRC cells and metastatic KIRC tissues. Subsequently, we found that SIX1 mediated metastasis and sunitinib resistance via Focal adhesion (FA) signaling, and knockdown of SIX1 enhanced the antitumor efficiency of sunitinib in KIRC. Mechanistically, Integrin subunit beta 1 (ITGB1), an upstream gene of FA signaling, was a direct transcriptional target of SIX1. In addition, we showed that DExH-box helicase 9 (DHX9) was an important mediator for SIX1-induced ITGB1 transcription, and silencing the subunits of SIX1/DHX9 complex significantly reduced transcription of ITGB1. Downregulation of SIX1 attenuated nuclear translocation of DHX9 and abrogated the binding of DHX9 to ITGB1 promoter. Collectively, our results unveiled a new signal axis SIX1/ITGB1/FAK in KIRC and identified a novel therapeutic strategy for metastatic KIRC patients.
Collapse
Affiliation(s)
- Shiyu Huang
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China
- Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China
- Central Laboratory, Renmin Hospital of Wuhan University, 430060, Wuhan, Hubei, China
| | - Juncheng Hu
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China
- Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China
| | - Min Hu
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China
| | - Yanguang Hou
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China
- Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China
| | - Banghua Zhang
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China
- Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China
- Hubei Key Laboratory of Digestive System Disease, Wuhan, 430060, China
| | - Jiachen Liu
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China
- Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China
| | - Xiuheng Liu
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
- Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
| | - Zhiyuan Chen
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
- Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
| | - Lei Wang
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
- Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
| |
Collapse
|
2
|
Ronghua W, Ji Z, Gang L, Yun Z, Xubiao N. Cystitis glandularis with concomitant Crohn's disease leading to a paroxysm of Crohn's disease with ulcerated external iliac vessels. BMC Urol 2024; 24:89. [PMID: 38632572 PMCID: PMC11022458 DOI: 10.1186/s12894-024-01470-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Accepted: 03/29/2024] [Indexed: 04/19/2024] Open
Abstract
•we report the case of a 36-year-old female patient who presented to our hospital with a diagnosis of cystitis glandularis manifesting as a vesicovaginal fistula. She underwent cystoscopic biopsy at a local hospital, but anti-inflammatory treatment was ineffective, and the patient was experiencing low urination frequency and urgency, as well as pain. The patient underwent laparoscopic repair of a cystoscopy-confirmed vesicovaginal fistula. After surgery, the patient experienced a paroxysm of Crohn's disease with multiple small bowel fistulas and erosion of the external iliac vessels that ruptured to form an external iliac vessel small bowel fistula. The fistula was confirmed by surgical exploration, and the patient eventually died.
Collapse
Affiliation(s)
- Wu Ronghua
- Department of Urology, Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China
| | - Zheng Ji
- Department of Urology, Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China
| | - Liu Gang
- Department of Intensive Care Unit, Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China
| | - Zhang Yun
- Department of Cardiovascular, Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China
| | - Nie Xubiao
- Department of Gastroenterology, Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
| |
Collapse
|
3
|
Huang S, Liu J, Hu J, Hou Y, Hu M, Zhang B, Luo H, Fu S, Chen Y, Liu X, Chen Z, Wang L. GHITM regulates malignant phenotype and sensitivity to PD-1 blockade of renal cancer cells via Notch signalling. J Cell Mol Med 2024; 28:e18290. [PMID: 38588015 PMCID: PMC11000813 DOI: 10.1111/jcmm.18290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2024] [Revised: 03/21/2024] [Accepted: 03/25/2024] [Indexed: 04/10/2024] Open
Abstract
Growth hormone inducible transmembrane protein (GHITM), one member of Bax inhibitory protein-like family, has been rarely studied, and the clinical importance and biological functions of GHITM in kidney renal clear cell carcinoma (KIRC) still remain unknown. In the present study, we found that GHITM was downregulated in KIRC. Aberrant GHITM downregulation related to clinicopathological feature and unfavourable prognosis of KIRC patients. GHITM overexpression inhibited KIRC cell proliferation, migration and invasion in vitro and in vivo. Mechanistically, GHITM overexpression could induce the downregulation of Notch1, which acts as an oncogene in KIRC. Overexpression of Notch1 effectively rescued the inhibitory effect induced by GHITM upregulation. More importantly, GHITM could regulate PD-L1 protein abundance and ectopic overexpression of GHITM enhanced the antitumour efficiency of PD-1 blockade in KIRC, which provided new insights into antitumour therapy. Furthermore, we also showed that YY1 could decrease GHITM level via binding to its promoter. Taken together, our study revealed that GHITM was a promising therapeutic target for KIRC, which could modulate malignant phenotype and sensitivity to PD-1 blockade of renal cancer cells via Notch signalling pathway.
Collapse
Affiliation(s)
- Shiyu Huang
- Department of UrologyRenmin Hospital of Wuhan UniversityWuhanHubeiChina
- Institute of Urologic Disease, Renmin Hospital of Wuhan UniversityWuhanHubeiChina
| | - Jiachen Liu
- Department of UrologyRenmin Hospital of Wuhan UniversityWuhanHubeiChina
- Institute of Urologic Disease, Renmin Hospital of Wuhan UniversityWuhanHubeiChina
- Central LaboratoryRenmin Hospital of Wuhan UniversityWuhanHubeiChina
| | - Juncheng Hu
- Department of UrologyRenmin Hospital of Wuhan UniversityWuhanHubeiChina
- Institute of Urologic Disease, Renmin Hospital of Wuhan UniversityWuhanHubeiChina
| | - Yanguang Hou
- Department of UrologyRenmin Hospital of Wuhan UniversityWuhanHubeiChina
- Institute of Urologic Disease, Renmin Hospital of Wuhan UniversityWuhanHubeiChina
| | - Min Hu
- Department of CardiologyRenmin Hospital of Wuhan UniversityWuhanHubeiChina
| | - Banghua Zhang
- Department of UrologyRenmin Hospital of Wuhan UniversityWuhanHubeiChina
- Institute of Urologic Disease, Renmin Hospital of Wuhan UniversityWuhanHubeiChina
- Hubei Key Laboratory of Digestive System DiseaseWuhanChina
| | - Hongbo Luo
- Department of UrologyRenmin Hospital of Wuhan UniversityWuhanHubeiChina
- Department of UrologyThe Second Hospital of HuangshiHuangshiChina
| | - Shujie Fu
- Department of UrologyRenmin Hospital of Wuhan UniversityWuhanHubeiChina
- Institute of Urologic Disease, Renmin Hospital of Wuhan UniversityWuhanHubeiChina
| | - Yujie Chen
- Department of UrologyRenmin Hospital of Wuhan UniversityWuhanHubeiChina
- Institute of Urologic Disease, Renmin Hospital of Wuhan UniversityWuhanHubeiChina
| | - Xiuheng Liu
- Department of UrologyRenmin Hospital of Wuhan UniversityWuhanHubeiChina
- Institute of Urologic Disease, Renmin Hospital of Wuhan UniversityWuhanHubeiChina
| | - Zhiyuan Chen
- Department of UrologyRenmin Hospital of Wuhan UniversityWuhanHubeiChina
- Institute of Urologic Disease, Renmin Hospital of Wuhan UniversityWuhanHubeiChina
| | - Lei Wang
- Department of UrologyRenmin Hospital of Wuhan UniversityWuhanHubeiChina
- Institute of Urologic Disease, Renmin Hospital of Wuhan UniversityWuhanHubeiChina
| |
Collapse
|
4
|
Jin X, Shang B, Wang J, Sun J, Li J, Liang B, Wang X, Su L, You W, Jiang S. Farnesoid X receptor promotes non-small cell lung cancer metastasis by activating Jak2/STAT3 signaling via transactivation of IL-6ST and IL-6 genes. Cell Death Dis 2024; 15:148. [PMID: 38360812 PMCID: PMC10869786 DOI: 10.1038/s41419-024-06495-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2023] [Revised: 01/22/2024] [Accepted: 01/23/2024] [Indexed: 02/17/2024]
Abstract
Metastasis accounts for the majority of cases of cancer recurrence and death in patients with advanced non-small cell lung cancer (NSCLC). Farnesoid X Receptor (FXR) is a bile acid nuclear receptor that was recently found to be upregulated in NSCLC tissues. However, whether and how FXR regulates NSCLC metastasis remains unclear. In the present study, it was found that FXR promoted the migration, invasion, and angiogenic ability of NSCLC cells in vitro, and increased NSCLC metastasis in a mouse model in vivo. Mechanistic investigation demonstrated that FXR specifically bound to the promoters of IL-6ST and IL-6 genes to upregulate their transcription, thereby leading to activation of the Jak2/STAT3 signaling pathway, which facilitated tumor migration, invasion, and angiogenesis in NSCLC. Notably, Z-guggulsterone, a natural FXR inhibitor, significantly reduced FXRhigh NSCLC metastasis, and decreased the expression of FXR, IL-6, IL-6ST, and p-STAT3 in the mouse model. Clinical analysis verified that FXR was positively correlated with IL-6, IL-6ST and p-STAT3 expression in NSCLC patients, and was indicative of a poor prognosis. Collectively, these results highlight a novel FXR-induced IL-6/IL-6ST/Jak2/STAT3 axis in NSCLC metastasis, and a promising therapeutic means for treating FXRhigh metastatic NSCLC.
Collapse
Affiliation(s)
- Xiuye Jin
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, Shandong, 250021, China
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250000, China
- Department of Respiratory and Critical Care Medicine, Xi'an Chest Hospital, Shanxi, 710100, China
| | - Bin Shang
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, Shandong, 250021, China
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250000, China
- Department of Thoracic Surgery, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China
- Department of Thoracic Surgery, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China
| | - Junren Wang
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, Shandong, 250021, China
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250000, China
| | - Jian Sun
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, Shandong, 250021, China
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250000, China
| | - Jing Li
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Public Health Clinical Center, Jinan, Shandong, 250013, China
| | - Bin Liang
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, Shandong, 250021, China
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250000, China
| | - Xingguang Wang
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, Shandong, 250021, China
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250000, China
| | - Lili Su
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, Shandong, 250021, China
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250000, China
| | - Wenjie You
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, Shandong, 250021, China.
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250000, China.
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
| | - Shujuan Jiang
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, Shandong, 250021, China.
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250000, China.
| |
Collapse
|
5
|
Nenkov M, Shi Y, Ma Y, Gaßler N, Chen Y. Targeting Farnesoid X Receptor in Tumor and the Tumor Microenvironment: Implication for Therapy. Int J Mol Sci 2023; 25:6. [PMID: 38203175 PMCID: PMC10778939 DOI: 10.3390/ijms25010006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 12/14/2023] [Accepted: 12/15/2023] [Indexed: 01/12/2024] Open
Abstract
The farnesoid-X receptor (FXR), a member of the nuclear hormone receptor superfamily, can be activated by bile acids (BAs). BAs binding to FXR activates BA signaling which is important for maintaining BA homeostasis. FXR is differentially expressed in human organs and exists in immune cells. The dysregulation of FXR is associated with a wide range of diseases including metabolic disorders, inflammatory diseases, immune disorders, and malignant neoplasm. Recent studies have demonstrated that FXR influences tumor cell progression and development through regulating oncogenic and tumor-suppressive pathways, and, moreover, it affects the tumor microenvironment (TME) by modulating TME components. These characteristics provide a new perspective on the FXR-targeted therapeutic strategy in cancer. In this review, we have summarized the recent research data on the functions of FXR in solid tumors and its influence on the TME, and discussed the mechanisms underlying the distinct function of FXR in various types of tumors. Additionally, the impacts on the TME by other BA receptors such as takeda G protein-coupled receptor 5 (TGR5), sphingosine-1-phosphate receptor 2 (S1PR2), and muscarinic receptors (CHRM2 and CHRM3), have been depicted. Finally, the effects of FXR agonists/antagonists in a combination therapy with PD1/PD-L1 immune checkpoint inhibitors and other anti-cancer drugs have been addressed.
Collapse
Affiliation(s)
- Miljana Nenkov
- Section Pathology of the Institute of Forensic Medicine, Jena University Hospital, Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany; (M.N.); (Y.M.); (N.G.)
| | - Yihui Shi
- California Pacific Medical Center Research Institute, Sutter Bay Hospitals, San Francisco, CA 94107, USA;
| | - Yunxia Ma
- Section Pathology of the Institute of Forensic Medicine, Jena University Hospital, Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany; (M.N.); (Y.M.); (N.G.)
| | - Nikolaus Gaßler
- Section Pathology of the Institute of Forensic Medicine, Jena University Hospital, Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany; (M.N.); (Y.M.); (N.G.)
| | - Yuan Chen
- Section Pathology of the Institute of Forensic Medicine, Jena University Hospital, Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany; (M.N.); (Y.M.); (N.G.)
| |
Collapse
|
6
|
Yang Y, Zhang M, Zhao Y, Deng T, Zhou X, Qian H, Wang M, Zhang C, Huo Z, Mao Z, Shao Z, Liu M, Yang C, Lin C, Xu F, Tian G, Zhang Y. HOXD8 suppresses renal cell carcinoma growth by upregulating SHMT1 expression. Cancer Sci 2023; 114:4583-4595. [PMID: 37752684 PMCID: PMC10728000 DOI: 10.1111/cas.15982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 09/11/2023] [Accepted: 09/15/2023] [Indexed: 09/28/2023] Open
Abstract
Amplification of amino acids synthesis is reported to promote tumorigenesis. The serine/glycine biosynthesis pathway is a reversible conversion of serine and glycine catalyzed by cytoplasmic serine hydroxymethyltransferase (SHMT)1 and mitochondrial SHMT2; however, the role of SHTM1 in renal cell carcinoma (RCC) is still unclear. We found that low SHMT1 expression is correlated with poor survival of RCC patients. The in vitro study showed that overexpression of SHMT1 suppressed RCC proliferation and migration. In the mouse tumor model, SHMT1 significantly retarded RCC tumor growth. Furthermore, by gene network analysis, we found several SHMT1-related genes, among which homeobox D8 (HOXD8) was identified as the SHMT1 regulator. Knockdown of HOXD8 decreased SHMT1 expression, resulting in faster RCC growth, and rescued the SHMT1 overexpression-induced cell migration defects. Additionally, ChIP assay found the binding site of HOXD8 to SHMT1 promoter was at the -456~-254 bp region. Taken together, SHMT1 functions as a tumor suppressor in RCC. The transcription factor HOXD8 can promote SHMT1 expression and suppress RCC cell proliferation and migration, which provides new mechanisms of SHMT1 in RCC tumor growth and might be used as a potential therapeutic target candidate for clinical treatment.
Collapse
Affiliation(s)
- Yang Yang
- School of PharmacyBinzhou Medical UniversityYantaiChina
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis, and TreatmentBinzhou Medical UniversityYantaiChina
| | - Minghui Zhang
- School of PharmacyBinzhou Medical UniversityYantaiChina
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis, and TreatmentBinzhou Medical UniversityYantaiChina
| | - Yaxuan Zhao
- School of PharmacyBinzhou Medical UniversityYantaiChina
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis, and TreatmentBinzhou Medical UniversityYantaiChina
| | - Tingzhi Deng
- School of PharmacyBinzhou Medical UniversityYantaiChina
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis, and TreatmentBinzhou Medical UniversityYantaiChina
| | - Xiang Zhou
- School of PharmacyBinzhou Medical UniversityYantaiChina
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis, and TreatmentBinzhou Medical UniversityYantaiChina
| | - Hanxu Qian
- School of PharmacyBinzhou Medical UniversityYantaiChina
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis, and TreatmentBinzhou Medical UniversityYantaiChina
| | - Mengxuan Wang
- School of PharmacyBinzhou Medical UniversityYantaiChina
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis, and TreatmentBinzhou Medical UniversityYantaiChina
| | - Chuanchuan Zhang
- School of PharmacyBinzhou Medical UniversityYantaiChina
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis, and TreatmentBinzhou Medical UniversityYantaiChina
| | - Zhengjin Huo
- The First School of Clinical MedicineBinzhou Medical UniversityYantaiChina
| | - Zijun Mao
- The First School of Clinical MedicineBinzhou Medical UniversityYantaiChina
| | - Zhufeng Shao
- School of PharmacyBinzhou Medical UniversityYantaiChina
| | - Mengxue Liu
- School of PharmacyBinzhou Medical UniversityYantaiChina
| | - Chunhua Yang
- School of PharmacyBinzhou Medical UniversityYantaiChina
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis, and TreatmentBinzhou Medical UniversityYantaiChina
| | - Chunhua Lin
- Department of UrologyThe Affiliated Yantai Yuhuangding Hospital of Qingdao UniversityYantaiChina
| | - Fuyi Xu
- School of PharmacyBinzhou Medical UniversityYantaiChina
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis, and TreatmentBinzhou Medical UniversityYantaiChina
| | - Geng Tian
- School of PharmacyBinzhou Medical UniversityYantaiChina
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis, and TreatmentBinzhou Medical UniversityYantaiChina
| | - Yin Zhang
- School of PharmacyBinzhou Medical UniversityYantaiChina
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis, and TreatmentBinzhou Medical UniversityYantaiChina
| |
Collapse
|
7
|
Zhong J, Yuan C, Liu L, Du Y, Hui Y, Chen Z, Diao C, Yang R, Liu G, Liu X. PCMT1 regulates the migration, invasion, and apoptosis of prostate cancer through modulating the PI3K/AKT/GSK-3β pathway. Aging (Albany NY) 2023; 15:11654-11671. [PMID: 37899170 PMCID: PMC10637816 DOI: 10.18632/aging.205152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Accepted: 09/26/2023] [Indexed: 10/31/2023]
Abstract
Protein L-isoaspartate (D-aspartate) O-methyltransferase (PCMT1) is a repair enzyme that catalyzes the conversion of isomerized aspartic acid (iso-Asp) residues into their normal structure, thereby restoring the configuration and function of proteins. Studies have shown that PCMT1 is overexpressed in several tumors and affects patients' prognosis. However, there are few reports on the role of PCMT1 in prostate cancer (PCa). In the present research, with the assistance of The Cancer Genome Atlas Program (TCGA) database, we found that PCMT1 was overexpressed in PCa tissues. The results of quantitative reverse transcription-polymerase chain reaction (qRT-PCR), western blot and immunohistochemistry staining also showed that PCMT1 expression was significantly increased in PCa tissues and cell lines. In PCa clinical samples, PCMT1 expression was closely related to Gleason score, clinical stage, lymph node metastasis and bone metastasis. The experiments of overexpression and knockdown of PCMT1 in vitro or in vivo showed that PCMT1 can significantly promote the proliferation, migration and invasion of PCa cells, inhibit cell apoptosis, and promote the growth of PCa. We furthermore confirmed that PCMT1 regulated the migration, invasion and apoptosis of PCa cells by modulating the phosphatidylinositol 3-kinase/AKT kinase/glycogen-synthase kinase-3β (PI3K/AKT/GSK-3β) signaling pathway. Collectively, PCMT1 plays a cancer-facilitative role in PCa by promoting the proliferation, migration and invasion of PCa cells, and inhibiting apoptosis. Therefore, PCMT1 is considered to represent a novel target for treating PCa.
Collapse
Affiliation(s)
- Jiacheng Zhong
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China
| | - Chao Yuan
- Department of Urology, Jingzhou Central Hospital, Jingzhou 434020, China
| | - Lin Liu
- Department of Emergency, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China
| | - Yang Du
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China
| | - Yumin Hui
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China
| | - Zhiyuan Chen
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China
| | - Changhui Diao
- Department of Urology, The First People’s Hospital of Shangqiu City, Shangqiu 476100, China
| | - Rui Yang
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China
| | - Guiyong Liu
- Department of Urology, Qianjiang Central Hospital, Qianjiang 433100, China
| | - Xiuheng Liu
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China
| |
Collapse
|
8
|
Hou Y, Liu J, Huang S, Wang L, Hu J, Liu X. DOT1L Epigenetically Regulates Autophagy and Mitochondria Fusion in Cell Lines of Renal Cancer. Technol Cancer Res Treat 2023; 22:15330338231167249. [PMID: 37365941 PMCID: PMC10538554 DOI: 10.1177/15330338231167249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Revised: 02/18/2023] [Accepted: 03/13/2023] [Indexed: 06/28/2023] Open
Abstract
OBJECTIVES DOT1L, a histone methylase, is overexpression in renal cell cancer. However, the role and detailed molecular mechanism of DOT1L involved in renal cancer development remain unknown. METHODS The inhibition of DOT1L was used by SGC0946 and short hairpin RNA silencing. Monodansylcadaverine staining and transmission electron microscope were performed to detect autophagy changes as a result of the inhibition of DOT1L. MitoTracker Red assay was used to analyze mitochondrial morphology. The autophagy markers and mitochondria-related proteins were analyzed by Western blot, qPCR, or immunofluorescence. ChIP assay was performed to demonstrate H3K79me2 is involved in the direct regulation of Farnesoid X receptor transcription. RESULTS DOT1L inhibition increased autophagy activity and promoted mito chondria fusion in cell lines of renal cancer. Inhibition of DOT1L upregulated levels of LC3α/β, P62, MFN1, and MFN2, which contributed to autophagy activity or mitochondria fusion. DOT1L knockdown showed a similar the above process. DOT1L inhibition or silencing resulted in AMP-activated protein kinase activation and mammalian target of rapamycin inhibition. Mechanistically, the DOT1L inhibitor and its short hairpin RNAs decreased the expression of Farnesoid X receptor in a histone methylase-dependent manner. CONCLUSION We revealed the essential role of Farnesoid X receptor in regulating DOT1L-induced autophagy and mitochondrial fission through the AMP-activated protein kinase/mammalian target of rapamycin pathway in cell lines of renal cancer, which may provide new insights into the pathogenesis of renal cell cancer.
Collapse
Affiliation(s)
- Yanguang Hou
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
- Wuhan University Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
| | - Jiachen Liu
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
- Wuhan University Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
| | - Shiyu Huang
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
- Wuhan University Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
| | - Lei Wang
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
| | - Juncheng Hu
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
- Wuhan University Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
| | - Xiuheng Liu
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
| |
Collapse
|